Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06530030 · ClinicalTrials.gov registry record
Goal Attainment and Physical Activity in People With Hemophilia A
A clinical trial, sponsored by Sanofi.
- Terminated
- Registry status
- 3
- Enrollment target
NCT06530030 is a clinical trial that was terminated before completion, run by Sanofi. The registered enrollment target is 3 participants.
The verdict
NCT06530030 was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- 3 participants
- Enrollment target
Study Summary
This is a Phase 4, multi-center, observational study conducted in patients aged 12 to 50 years with moderate or severe hemophilia A who are newly starting prophylaxis with efa in the US and Japan. This study aims to enroll 35 patients.
Interventions
- DRUG efanesoctocog alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2024-11-26 |
| Est. Completion | 2025-09-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06530030
The ClinicalTrials.gov registry entry for NCT06530030 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which efanesoctocog alfa is the first listed.
NCT06530030 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06530030 about?
NCT06530030 is a clinical study titled "Goal Attainment and Physical Activity in People With Hemophilia A". This is a Phase 4, multi-center, observational study conducted in patients aged 12 to 50 years with moderate or severe hemophilia A who are newly starting prophylaxis with efa in the US and Japan. This study aims to enroll 35 patients.
What is the current status of trial NCT06530030?
This trial is currently terminated. The enrollment target is 3 participants. The study started on 2024-11-26. Estimated completion is 2025-09-18.
What interventions are being tested in trial NCT06530030?
The interventions under investigation include: efanesoctocog alfa (DRUG).
Who is sponsoring clinical trial NCT06530030?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.